Nerve, muscle and heart acute toxicity following oxaliplatin and capecitabine treatment

Neuromuscular Disorders

Volumn 22, Issue 8, 2012, Pages 767-770

  Orsucci, Daniele ^a   Pizzanelli, Chiara ^a   Alì, Greta ^a   Calabrese, Rosanna ^a   Ricci, Giulia ^a   Lenzi, Paola ^a   Petrozzi, Lucia ^a   Moretti, Policarpo ^a   Siciliano, Gabriele ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

Mitochondria; MtDNA; Necrotizing myopathy; Neurotoxicity; Toxic myopathy; Toxic neuropathy

Indexed keywords

CAPECITABINE PLUS OXALIPLATIN; CREATINE KINASE; IMMUNOGLOBULIN; METHYLPREDNISOLONE;

ADULT; ANOREXIA; ARTICLE; ASTHENIA; BONE MARROW TOXICITY; CARDIOTOXICITY; CASE REPORT; CREATINE KINASE BLOOD LEVEL; ECHOCARDIOGRAPHY; ELECTROMYOGRAPHY; FATIGUE; FEMALE; HEART LEFT VENTRICLE FAILURE; HUMAN; HUMAN TISSUE; HYPESTHESIA; LIMB DYSESTHESIA; LIVER METASTASIS; MULTIPLE CYCLE TREATMENT; MUSCLE BIOPSY; MUSCLE WEAKNESS; MYOPATHY; NEUROTOXICITY; PARAPLEGIA; PARESTHESIA; POLYNEUROPATHY; PRIORITY JOURNAL; RECTUM CARCINOMA; RECTUM SURGERY; REFLEX DISORDER; TOXIC MYOPATHY;

ADENOCARCINOMA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARDIOMYOPATHIES; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; FEMALE; FLUOROURACIL; HUMANS; MIDDLE AGED; NEUROMUSCULAR DISEASES; ORGANOPLATINUM COMPOUNDS;

EID: 84863865601     PISSN: 09608966     EISSN: 18732364     Source Type: Journal    
DOI: 10.1016/j.nmd.2012.04.004     Document Type: Article

References (13)

1. Schmoll H.J., Arnold D. Update on capecitabine in colorectal cancer. Oncologist 2006, 11:1003-1009.
2. Gamelin L., Capitain O., Morel A., et al. Predictive factors of oxaliplatin neurotoxicity: the involvement of the oxalate outcome pathway. Clin Cancer Res 2007, 13:6359-6368.
3. Milano G., Etienne-Grimaldi M.C., Mari M., et al. Candidate mechanisms for capecitabine-related hand-foot syndrome. Br J Clin Pharmacol 2008, 66:88-95.
4. Molteni L.P., Rampinelli I., Cergnul M., et al. Capecitabine in breast cancer: the issue of cardiotoxicity during fluoropyrimidine treatment. Breast J 2010, 16(Suppl. 1):S45-48.
5. Argov Z., Mastaglia K.F. Endocrine and toxic myopathies. Disorders of voluntary muscle 2010, 471-483. Cambridge University Press. 8th ed. G. Karpati, D. Hilton-Jones, K. Bushby, R.C. Griggs (Eds.).
6. Alcindor T., Beauger N. Oxaliplatin: a review in the era of molecularly targeted therapy. Curr Oncol 2011, 18:18-25.
7. Goshima Y., Usui H., Shiozawa T., et al. Computational analysis of the effects of antineoplastic agents on axonal transport. J Pharmacol Sci 2010, 114:168-179.
8. Carozzi V.A., Marmiroli P., Cavaletti G. The role of oxidative stress and anti-oxidant treatment in platinum-induced peripheral neurotoxicity. Curr Cancer Drug Targets 2010, 10:670-682.
9. Le Brun-Ly V., Martin J., Venat-Bouvet L., et al. Cardiac toxicity with capecitabine, vinorelbine and trastuzumab therapy: case report and review of fluoropyrimidine-related cardiotoxicity. Oncology 2009, 76:322-325.
10. Fantini M., Gianni L., Tassinari D., et al. Toxic encephalopathy in elderly patients during treatment with capecitabine: literature review and a case report. J Oncol Pharm Pract 2011, 17:288-291.
11. Sieb J.P., Gillessen T. Iatrogenic and toxic myopathies. Muscle Nerve 2003, 27:142-156.
12. Schoser B. Physiology, pathophysiology and diagnostic significance of autophagic changes in skeletal muscle tissue - towards the enigma of rimmed and round vacuoles. Clin Neuropathol 2009, 28:59-70.
13. Mancuso M., Orsucci D., Filosto M., Simoncini C., Siciliano G. Drugs and mitochondrial diseases: 40 queries and answers. Expert Opin Pharmacother 2012, 13:527-543.